Among clinical responders with known allelic status, 78% (7/9) had biallelic LOF, including two patients with germline BRCA1-altered ovarian cancer previously treated with PARPi and platinum therapy (Table 3). The gene discussed is BRCA1; the disease is ovarian carcinoma.